Rev-erb? agonist SR9009 guards from cerebral ischemic harm by mechanisms involving Nrf2 pathwayIt entered scientific development like a drug prospect for metabolic and cardiovascular disease states, owing it’s promising Advantages on blood lipid concentrations.= eight for each team). ATRA was administrated intraperitoneally at doses of 10 mg/k